Organogenesis Holdings Inc. (ORGO) Financial Statements
Organogenesis Holdings Inc. (ORGO) reported trailing twelve-month revenue of $457.5M (up 6.5% year on year) and net income of -$84.2M as of 2026-06-30, according to EquiReason's reading of its SEC filings. Free cash flow over the same period: $20.8M.
Source: SEC EDGAR filings · figures as of 2026-06-30 · read by EquiReason
ORGOOrganogenesis Holdings Inc.Follow ORGO — free
—
Price chart with a free account
- Market cap
- 127.8M
- P/E TTM
- —
- Dividend yield
- —
- 52-week
- —
- Next earnings
- 5 Nov, in 12 days
Fiscal-year columns end in the month shown. The current fiscal year appears once its annual report is filed; until then TTM = the last four reported quarters, to Jun 26.
| Line | FY2018 Dec 18 | FY2019 Dec 19 | FY2020 Dec 20 | FY2021 Dec 21 | FY2022 Dec 22 | FY2023 Dec 23 | FY2024 Dec 24 | FY2025 Dec 25 | TTM Jun 26 | Trend |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 193.4 | 261.0 | 338.3 | 467.4 | 450.9 | 433.1 | 482.0 | 564.2 | 457.5 | |
| Gross profit | 124.6 | 185.0 | 251.0 | 353.2 | 345.9 | 326.7 | 366.3 | — | — | |
| Research & development | 10.7 | 14.8 | 20.1 | 30.7 | 39.8 | 44.4 | 50.3 | 44.5 | 57.0 | |
| Operating income | -51.6 | -29.9 | 26.7 | 72.2 | 22.3 | 12.5 | -1.3 | 44.7 | -35.9 | |
| Pre-tax income | -64.7 | -38.6 | 17.8 | 63.1 | 20.3 | 10.4 | -2.8 | 47.0 | -34.8 | |
| Income tax | 0.1 | 0.2 | 0.5 | -31.1 | 4.8 | 5.4 | -3.7 | 9.9 | 49.4 | |
| Net income | -64.8 | -38.7 | 17.2 | 94.2 | 15.5 | 4.9 | 0.9 | 37.0 | -84.2 | |
| Diluted EPS ($) | -0.94 | -0.44 | 0.15 | 0.70 | 0.12 | 0.04 | -0.01 | 0.15 | -0.83 | |
| Diluted shares (mn) | — | — | 111.4 | 133.7 | 132.4 | 132.7 | 131.7 | 130.2 | — |
USD millions · SEC XBRL
Organogenesis Holdings Inc. — questions
- What is Organogenesis Holdings Inc.'s revenue?
- $457.5M over the twelve months to 2026-06-30, up 6.5% year on year, from its 10-Q and 10-K filings.
- What is Organogenesis Holdings Inc.'s net income?
- -$84.2M over the twelve months to 2026-06-30.
- What is Organogenesis Holdings Inc.'s free cash flow?
- $20.8M over the twelve months to 2026-06-30.
- What are Organogenesis Holdings Inc.'s diluted earnings per share?
- $-0.83 over the twelve months to 2026-06-30.
Every figure on this page comes from Organogenesis Holdings Inc.'s own SEC filings — see them on SEC EDGAR. Price data is licensed and shown only inside the product.
How these figures are read: methodology · EquiReason.